Inventor · disambiguated record
Douglas Kirk Ways
Also filed as: WAYS DOUGLAS K · WAYS DOUGLAS KIRK
15 granted patents·6 pending applications·164 citations·filing 1996–2020
93Inventor score
Top patents by PatentIndex Score
21 records- 0187US6486179B2Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapyLILLY CO ELI·Filed 2001·Granted Nov 26, 2002·22 cites·1 claims
- 0278US11207337B2Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disordersJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Dec 28, 2021·1 cites·10 claims
- 0370US6284751B1Therapeutic treatment for VEGF related diseasesLILLY CO ELI·Filed 1999·Granted Sep 4, 2001·30 cites·4 claims
- 0464US6114320ATherapeutic treatment for VEGF related ocular diseasesLILLY CO ELI·Filed 1997·Granted Sep 5, 2000·21 cites·12 claims
- 0564US6093740ATherapeutic treatment for skin disordersLILLY CO ELI·Filed 1998·Granted Jul 25, 2000·20 cites·10 claims
- 0661US6232299B1Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapyLILLY CO ELI·Filed 1997·Granted May 15, 2001·14 cites·6 claims
- 0759US2016022632A1Combination of canagliflozin and probenecid for the treament of hyperuricemiaJANSSEN PHARMACEUTICA NV·Filed 2014·Application pending·0 cites
- 0857US5723456ATherapeutic treatment for cardiovascular diseasesLILLY CO ELI·Filed 1996·Granted Mar 3, 1998·13 cites·50 claims
- 0952US6093709ATherapeutic treatment for sexual dysfunctionsLILLY CO ELI·Filed 1997·Granted Jul 25, 2000·9 cites·18 claims
- 1052US2019142855A1Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disordersJANSSEN PHARMACEUTICA NV·Filed 2019·Application pending·0 cites
- 1151US2018353470A1Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitusJANSSEN PHARMACEUTICA NV·Filed 2018·Application pending·0 cites
- 1250US2021000792A1Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitusJANSSEN PHARMACEUTICA NV·Filed 2020·Application pending·0 cites
- 1349US6291446B1Therapeutic treatment for cytomegalovirus infectionLILLY CO ELI·Filed 1999·Granted Sep 18, 2001·11 cites·12 claims
- 1446US2017368025A1Combination of canagliflozin and probenecid for the treament of hyperuricemiaJANSSEN PHARMACEUTICA NV·Filed 2017·Application pending·0 cites
- 1545US6107327ATherapeutic treatment for HIV infectionLILLY CO ELI·Filed 1997·Granted Aug 22, 2000·5 cites·24 claims
- 1645US2017071970A1Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disordersJANSSEN PHARMACEUTICA NV·Filed 2016·Application pending·0 cites
- 1740US6225301B1Therapeutic treatment for renal dysfunctionLILLY CO ELI·Filed 1999·Granted May 1, 2001·6 cites·18 claims
- 1840US6103713ATherapeutic treatment for autoimmune diseasesLILLY CO ELI·Filed 1999·Granted Aug 15, 2000·9 cites·20 claims
- 1937US6103712ATherapeutic treatment for asthmaLILLY CO ELI·Filed 1999·Granted Aug 15, 2000·2 cites·12 claims
- 2035US6288053B1Use of protein kinase C inhibitors to enhance the clinical efficacy of radiation therapyLILLY CO ELI·Filed 1998·Granted Sep 11, 2001·1 cites·3 claims
- 2131US5962446ATherapetutic treatment for human T cell lymphotrophic virus type 1 infectionLILLY CO ELI·Filed 1997·Granted Oct 5, 1999·0 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when Douglas Kirk Ways files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →